The partnership leverages the Hesperos organ-on-a-chip platform in the preclinical development of Psilera’s lead compound ...

FTD is a progressive neurodegenerative disorder with limited treatment options. The integration of next-generation ...

Psilera, a Tampa-based biotech company, has taken a significant step in advancing treatments for dementia with its psilocybin ...

Next-generation R&D psychedelics company Psilera Inc. shared its two proprietary DMT analogs PSIL-001 and PSIL-002’s preclinical positive results for mental health disorder treatments.

Bolstered by the latest preclinical data, Psilera is poised to advance their lead asset, PSIL-006, towards first-in-human studies for Frontotemporal Dementia (FTD). "From the start, our primary ...

A white paper action plan will be released by Psilera later this year. Psilera convenes FTD leaders to advance research and patient care. "This event started as a "what if…" idea that quickly ...

TAMPA, Fla. and NEW YORK and BERLIN, Feb. 20, 2025 /PRNewswire/ -- Psilera, Inc. ("Psilera"), a biotechnology company developing groundbreaking therapies for hard-to-treat neurological disorders ...

Psilera has secured funding to advance its research on Frontotemporal Dementia, a condition currently lacking effective treatments. The University of South Florida Research Foundation has invested ...

"This event started as a "what if…" idea that quickly grew to become a robust conversation between many passionate and brilliant professionals all working towards a common goal," said Dr. Chris ...